Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. VCEL
VCEL logo

VCEL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Vericel Corp (VCEL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
35.130
1 Day change
-4.49%
52 Week Range
45.970
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Vericel Corp (VCEL) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company shows solid financial growth and analysts maintain a positive outlook, the lack of immediate trading signals, neutral technical indicators, and cautious options sentiment suggest that waiting for a more favorable entry point might be prudent.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 50.592, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 34.542, with resistance at 35.691 and support at 33.392.

Options Data

Bearish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
5

Positive Catalysts

  • Strong financial performance in Q4 2025 with revenue up 23.27% YoY, net income up 17.35% YoY, and EPS up 21.21% YoY. Analysts highlight above-20% growth prospects and emerging profitability.

Neutral/Negative Catalysts

  • No recent news or significant insider/hedge fund activity. Technical indicators are neutral, and short-term stock trend analysis suggests minor downside potential.

Financial Performance

In Q4 2025, Vericel reported revenue of $92.92M (up 23.27% YoY), net income of $23.24M (up 17.35% YoY), EPS of $0.4 (up 21.21% YoY), and gross margin of 78.7% (up 1.40% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a Buy rating with price targets ranging from $42 to $64. Truist recently lowered its target from $48 to $42, citing cautious investor sentiment, but highlighted the company's strong growth and profitability prospects. H.C. Wainwright raised its target to $64, citing conservative revenue outlook and strong Q1 sales growth.

Wall Street analysts forecast VCEL stock price to rise
5 Analyst Rating
Wall Street analysts forecast VCEL stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 36.780
sliders
Low
55
Averages
57.67
High
60
Current: 36.780
sliders
Low
55
Averages
57.67
High
60
Truist
Buy
downgrade
$48 -> $42
AI Analysis
2026-04-15
Reason
Truist
Price Target
$48 -> $42
AI Analysis
2026-04-15
downgrade
Buy
Reason
Truist lowered the firm's price target on Vericel to $42 from $48 but keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds that the stock should be able to sustain a premium relative to its SMID peers given the company's above-20% growth prospects and emerging/accelerating profitability.
H.C. Wainwright
Buy
maintain
$60 -> $64
2026-02-27
Reason
H.C. Wainwright
Price Target
$60 -> $64
2026-02-27
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Vericel to $64 from $60 and keeps a Buy rating on the shares following the Q4 report. The company's 2026 revenue outlook is conservative given that Vericel noted Q1 sales growth is already trending towards 20%, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for VCEL
Unlock Now

People Also Watch